GLP-1 medications are a class of drugs that mimic a natural gut hormone called glucagon-like peptide-1, which your body releases after eating. They were originally developed to treat type 2 diabetes but have become widely known for their significant effects on weight loss. The most recognized names in this class are semaglutide (sold as Ozempic and Wegovy) and tirzepatide (sold as Mounjaro and Zepbound), though several others exist.
How GLP-1 Medications Work
After you eat, your gut naturally produces GLP-1 to help manage blood sugar. This hormone triggers several responses at once: it signals your pancreas to release insulin, it tells your liver to stop dumping extra sugar into your bloodstream, and it slows down how fast food leaves your stomach. In people with type 2 diabetes, this system often stops working properly. GLP-1 medications deliver the hormone at much higher levels than your body produces on its own, essentially restoring and amplifying these effects.
The slowed stomach emptying is a big part of why these drugs reduce appetite. Food sits in your stomach longer, so you feel full sooner and stay full longer. GLP-1 receptors also exist in the brain, where the medication appears to dampen food cravings and reduce the reward signals associated with eating. This combination of gut-level and brain-level effects is what makes GLP-1 drugs more effective for weight loss than most previous medications.
What They’re Approved to Treat
GLP-1 medications carry FDA approval for two primary uses: type 2 diabetes and chronic weight management. Not every drug in the class is approved for both. Ozempic, for instance, is approved specifically for diabetes, while Wegovy (the same compound, semaglutide, at a higher dose) is approved for weight management. Tirzepatide follows a similar split between its brand names. The weight management approvals generally apply to adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related health condition like high blood pressure or high cholesterol.
Injectable vs. Oral Options
Most GLP-1 medications are given as subcutaneous injections, meaning you inject them into the fat just under your skin, typically in the abdomen, thigh, or upper arm. The convenience factor has improved considerably over the years. Early GLP-1 drugs required twice-daily injections, but the most commonly prescribed versions today are once-weekly shots using a pre-filled pen that looks similar to an insulin pen.
An oral version of semaglutide became available in 2019, making it the first pill option in this drug class. It’s taken daily rather than weekly, at doses of 7 or 14 mg. The oral form requires specific timing: you take it on an empty stomach with no more than 4 ounces of plain water, then wait at least 30 minutes before eating or drinking anything else. This is because the tablet needs an empty, low-acid environment to be absorbed properly.
Blood Sugar Control in Diabetes
For people with type 2 diabetes, GLP-1 medications typically lower HbA1c (a measure of average blood sugar over three months) by 1.0% to 2.0%. That’s a meaningful drop. To put it in perspective, an HbA1c of 8% falling to 6.5% or 7% can be the difference between uncontrolled diabetes and hitting a treatment target. Real-world studies show somewhat variable results, with injectable semaglutide producing HbA1c reductions ranging from 0.3% to 3.4% depending on the individual patient, their starting levels, and how long they stay on the medication.
One important feature of these drugs is that they work in a glucose-dependent way. They stimulate insulin release primarily when blood sugar is elevated, which means the risk of dangerous low blood sugar (hypoglycemia) is much lower compared to some older diabetes medications like sulfonylureas or insulin itself.
Weight Loss Results
The weight loss numbers from clinical trials are striking compared to previous obesity medications. In the landmark STEP-1 trial, people without diabetes who took semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks. For someone weighing 250 pounds, that translates to roughly 37 pounds.
Tirzepatide, which targets both GLP-1 and a second gut hormone receptor called GIP, produced even larger results. In the SURMOUNT-1 trial, participants lost between 15.0% and 20.9% of their body weight depending on dose, over 72 weeks. At the highest dose, that’s a fifth of total body weight, which approaches what was previously only achievable through bariatric surgery.
These are averages, though. Individual results vary widely. Some people lose considerably more, others less. And the weight loss is not permanent if you stop the medication. Most studies show significant weight regain after discontinuation, which is why these drugs are generally considered long-term treatments rather than short courses.
Heart and Kidney Benefits
Beyond blood sugar and weight, GLP-1 medications appear to protect the cardiovascular system. A large meta-analysis found that these drugs reduce major adverse cardiovascular events (heart attack, stroke, or cardiovascular death) by 12% compared to placebo. This benefit has been observed even after accounting for improvements in blood sugar and weight, suggesting the drugs may have direct protective effects on blood vessels and the heart.
There are also signals of kidney protection. Studies have shown that patients taking GLP-1 medications have significantly lower rates of kidney damage progression, including less protein leakage into urine and fewer cases advancing to kidney failure. Research is also underway examining whether these drugs can treat fatty liver disease, a condition closely linked to obesity and diabetes. Early results are promising, though no GLP-1 drug has received FDA approval for liver disease yet.
Common Side Effects
Gastrointestinal problems are by far the most frequent side effects, which makes sense given that these drugs work partly by slowing your digestive system. Across the drug class, roughly 1 in 5 people experience nausea, making it the most common complaint. Diarrhea affects about 11%, vomiting about 9%, and constipation around 8%. Reduced appetite, while technically a side effect, is often the intended effect for people using these drugs for weight management.
The severity varies by medication. Exenatide tends to cause the most nausea (about 32% of users), while dulaglutide causes the least (around 10%). Semaglutide and tirzepatide fall in between at roughly 21% and 25%, respectively. For most people, nausea is worst during the first few weeks and during dose increases, then gradually fades. Starting at a low dose and increasing slowly, which is the standard prescribing approach, helps minimize these effects.
Safety Considerations
GLP-1 medications carry a boxed warning about thyroid tumors based on animal studies, where rodents developed a specific type called medullary thyroid carcinoma. This finding has not been replicated in humans. Clinical trials lasting three years or more have not shown increased thyroid cancer risk or changes in calcitonin (a hormone marker for that cancer type) in people taking these drugs. Still, they are not prescribed to anyone with a personal or family history of medullary thyroid carcinoma or a rare genetic condition called multiple endocrine neoplasia type 2.
People with a history of pancreatitis are also generally advised against using GLP-1 medications, as there have been reports of inflammation of the pancreas during treatment. The drugs should not be combined with certain other diabetes medications that work through similar pathways, and they aren’t used in type 1 diabetes.
Cost and Access
Price remains the biggest barrier to GLP-1 medications. Without insurance, the most popular options cost around $1,000 per month, and even lower-cost alternatives in the class run several hundred dollars monthly. Insurance coverage varies significantly. Many plans cover these drugs for type 2 diabetes but not for weight management, and those that do cover weight management often require documentation of failed diet and exercise attempts or proof of weight-related health conditions.
The high demand has also caused periodic supply shortages, particularly for semaglutide products. Compounding pharmacies have filled some of the gap by producing custom versions, though the FDA has raised concerns about the quality and safety of some compounded products. If you’re exploring this option, verifying that any compounding pharmacy is properly licensed and uses FDA-approved ingredients is worth the effort.